Merck (MRK) Acquisitions (2009 - 2026)

Merck (MRK) posted quarterly Acquisitions of $8.8 billion for Q1 2026, down 12.58% quarter-over-quarter from $10.0 billion in Q4 2025.

Merck (MRK) Acquisitions (2009 - 2026) Analysis & Trends

Merck (MRK) has reported Acquisitions for 15 consecutive years, with $8.8 billion the latest figure, recorded in Q1 2026.

In Q1 2026, Acquisitions changed N/A year-over-year to $8.8 billion; the TTM figure through Mar 2026 stood at $18.8 billion (up 2622.92% YoY), while the FY2025 annual figure was $10.0 billion, changed N/A from the prior year.
Acquisitions fell to $8.8 billion in Q1 2026 per MRK's latest filing, from $10.0 billion in the prior quarter.
Across five years, Acquisitions topped out at $10.0 billion in Q4 2025 and bottomed at -$1.3 billion in Q4 2024.
Historically, Acquisitions has averaged $2.7 billion across 4 years, with a median of $598.0 million in 2024.
On a YoY basis, Acquisitions climbed as much as 12200.0% in 2022 and fell as far as 234.44% in 2022.
Merck's Acquisitions stood at -$121.0 million in 2022, then plunged by 1010.74% to -$1.3 billion in 2024, then jumped by 847.17% to $10.0 billion in 2025, then retreated by 12.58% to $8.8 billion in 2026.
Business Quant data shows MRK's Acquisitions at $8.8 billion in Q1 2026, $10.0 billion in Q4 2025, and -$1.3 billion in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn	-17.24 Bn
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn	-
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn	-
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn	-
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn	-
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn	-
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn	11.21 Bn
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn	-
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn	-
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn	-

Download Data